Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$240.71+0.94 (+0.39%)
Close on Nov 17, 2026Market cap $15.63BP/E 78.4Yield –
Jazz Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Jazz Pharmaceuticals's pe ratio was 17.0× on Nov 11, 2026, against 17.1× a year earlier. Over the last 5 years it ranged from 11.0× to 178.3×, with a median of 18.9×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 17.0× | +1.7 |
| 2025 | Jul 31, 2025 | 15.3× | −2.1 |
| 2024 | Dec 31, 2024 | 17.3× | −160.9 |
| 2023 | Dec 29, 2023 | 178.3× | +38.2 |
| 2021 | Oct 29, 2021 | 140.0× | +88.0 |
| 2020 | Dec 31, 2020 | 52.1× | +37.8 |
| 2019 | Dec 31, 2019 | 14.3× | −0.4 |
| 2018 | Dec 31, 2018 | 14.7× | −7.5 |
| 2017 | Dec 29, 2017 | 22.2× | +3.5 |
| 2016 | Dec 30, 2016 | 18.7× | −8.3 |
| 2015 | Dec 31, 2015 | 27.0× | −353.8 |
| 2014 | Dec 31, 2014 | 380.8× | +359.4 |
| 2013 | Dec 31, 2013 | 21.4× | −2.0 |
| 2012 | Dec 31, 2012 | 23.5× | +9.0 |
| 2011 | Dec 30, 2011 | 14.5× | – |
See a number that looks wrong?